{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Prostate&page=37", "query": { "condition": "Cancer, Prostate", "page": 37 }, "page_size": 10 }, "pagination": { "page": 37, "page_size": 10, "total_count": 3919, "total_pages": 392, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Prostate&page=38&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Prostate&page=36&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T03:33:15.214Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00054574", "title": "Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "panitumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "18 Years to 120 Years · Male only" }, "enrollment_count": null, "start_date": "2002-11", "completion_date": "2004-02", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-11-15T03:33:15.214Z", "location_count": 2, "location_summary": "Los Angeles, California • Philadelphia, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054574" }, { "nct_id": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Colon Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Esophageal Carcinoma", "Exocrine Pancreas Carcinoma", "Gastric Carcinoma", "Glioma", "Head and Neck Carcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Kidney Carcinoma", "Liver Carcinoma", "Lung Carcinoma", "Lymphoma", "Malignant Uterine Corpus Neoplasm", "Malignant Uterine Neoplasm", "Melanoma", "Multiple Myeloma", "Ovarian Carcinoma", "Prostate Carcinoma", "Rectal Carcinoma", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Colon Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Glioma", "Recurrent Head and Neck Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Melanoma", "Recurrent Multiple Myeloma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Rectal Carcinoma", "Recurrent Skin Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma", "Skin Carcinoma", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Afatinib Dimaleate", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Defactinib", "type": "DRUG" }, { "name": "Defactinib Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Fexagratinib", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib", "type": "DRUG" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "PI3K-beta Inhibitor GSK2636771", "type": "DRUG" }, { "name": "Radiologic Examination", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Taselisib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6452, "start_date": "2015-08-17", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T03:33:15.214Z", "location_count": 1405, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465060" }, { "nct_id": "NCT02643303", "title": "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Breast Cancer", "Sarcoma", "Merkel Cell Carcinoma", "Cutaneous T-Cell Lymphoma", "Melanoma", "Renal Cancer", "Bladder Cancer", "Prostate Cancer", "Testicular Cancer", "Solid Tumor" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Poly-ICLC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ludwig Institute for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2016-12-28", "completion_date": "2022-02-23", "has_results": true, "last_update_posted_date": "2022-12-02", "last_synced_at": "2026-11-15T03:33:15.214Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Lebanon, New Hampshire • Buffalo, New York + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02643303" }, { "nct_id": "NCT01443026", "title": "The Effects of Lycopene on High Risk Prostatic Tissue", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intraepithelial Prostatic Neoplasia", "Prostatic Neoplasms" ], "interventions": [ { "name": "Lycopene 30mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "MALE", "summary": "40 Years and older · Male only" }, "enrollment_count": 66, "start_date": "2006-02", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2019-11-19", "last_synced_at": "2026-11-15T03:33:15.214Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01443026" }, { "nct_id": "NCT06120491", "title": "Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-Sensitive Prostate Cancer" ], "interventions": [ { "name": "Saruparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "18 Years to 130 Years · Male only" }, "enrollment_count": 1898, "start_date": "2023-11-21", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2026-11-10", "last_synced_at": "2026-11-15T03:33:15.214Z", "location_count": 71, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 63 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120491" }, { "nct_id": "NCT01764347", "title": "Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Image-Guided Prostate Biopsy Following Radical Prostatectomy in Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "ultrasound-guided prostate biopsy", "type": "PROCEDURE" }, { "name": "magnetic resonance imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 24, "start_date": "2010-11", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-01-28", "last_synced_at": "2026-11-15T03:33:15.214Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01764347" }, { "nct_id": "NCT07723248", "title": "A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Rinzimetostat", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ORIC Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 600, "start_date": "2026-08-03", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-15T03:33:15.214Z", "location_count": 14, "location_summary": "Glendale, California • Coral Springs, Florida • Jeffersonville, Indiana + 11 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Jeffersonville", "state": "Indiana" }, { "city": "Holland", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07723248" }, { "nct_id": "NCT00681148", "title": "Botulinum Toxin Injection With Prostate Brachytherapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Lower Urinary Tract Symptoms", "Radioactive Seed Implantation" ], "interventions": [ { "name": "Botox injection", "type": "DRUG" }, { "name": "Saline injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": null, "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2013-11-21", "last_synced_at": "2026-11-15T03:33:15.214Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00681148" }, { "nct_id": "NCT06582849", "title": "Enhanced Assistance During Radiotherapy for Unmet Essential Needs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bone Cancer", "Brain Cancer", "Colorectal Cancer", "Esophagus Cancer", "Lymphoma", "Salivary Gland Cancer", "Head and Neck Cancer", "Liver Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Small Intestine Cancer", "Stomach Cancer", "Urinary Bladder Cancer", "Anal Cancer", "Blood Cancer", "Breast Cancer", "Cervical Cancer", "Lung Cancer", "Kidney Cancer", "Penile Cancer", "Skin Cancer", "Testicular Cancer", "Thyroid Cancer", "Uterine Cancer", "Vaginal Cancer", "Vulvar Cancer" ], "interventions": [ { "name": "Standard assistance", "type": "OTHER" }, { "name": "Enhanced assistance", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2024-10-04", "completion_date": "2025-08-08", "has_results": false, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-11-15T03:33:15.214Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06582849" }, { "nct_id": "NCT07550517", "title": "PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High-Risk Localized Prostate Cancer" ], "interventions": [ { "name": "EBRT + 6 mo ADT + 177Lu-PSMA-617", "type": "DRUG" }, { "name": "EBRT + 24 mo ADT", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2026-08-17", "completion_date": "2033-08", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-11-15T03:33:15.214Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07550517" } ] }